GST: A Potential Drug Target Or Biomarker (P11290)

Target Name: Glutathione S-Transferase (GST)

NCBI ID: P11290

Glutathione S-Transferase (GST)

Other Name(s): GST | Glutathione S-Transferase

GST: A Potential Drug Target Or Biomarker

Glutathione S-Transferase (GST) is a enzyme that plays a crucial role in the immune system and the production of important proteins in the body. There are several subtypes of GST, including nonspecific subtype (GST), which is a potential drug target or biomarker.

GST is a transmembrane protein that is expressed in a variety of tissues throughout the body, including the liver, spleen, and intestine. It is a member of the family of transmembrane proteinases, which are a type of enzyme that spans the cell membrane and functions outside the cell. GST is responsible for breaking down a variety of molecules, including proteins, neurotransmitters, and other substances that are harmful to the body.

GST is involved in the production of several important proteins, including the immune protein known as interleukin-2 (IL-2). IL-2 is a cytokine that is critical for the development and maintenance of a healthy immune system. It is produced by T-cells and other immune cells in the body and plays a vital role in the fight against infection and disease.

GST is also involved in the production of other important proteins, including the enzyme superoxide dismutase (SOD), which is responsible for breaking down superoxide, a toxic compound that can damage cells and contribute to a variety of diseases, including cancer.

GST is also involved in the production of the protein heparan sulfate, which is a major component of connective tissue and is involved in the formation of many important tissues in the body, including bones, skin, and blood vessels.

GST is a potential drug target or biomarker because of its involvement in the production of important proteins that are involved in a variety of biological processes. Many diseases, including cancer, autoimmune disorders, and neurodegenerative diseases, are caused by the production of abnormal proteins or the failure of normal proteins to function properly. By targeting GST, researchers may be able to develop new treatments for these diseases.

In addition to its involvement in the production of important proteins, GST is also a potential biomarker for a variety of diseases. The levels of GST in certain tissues, such as the liver and spleen, can be increased in response to the production of certain proteins or the presence of certain substances in the body. This may make GST a useful diagnostic tool for diseases that affect these tissues, such as liver or spleen cancer.

GST is also a potential drug target for a variety of other diseases, including neurodegenerative disorders and autoimmune disorders. Many of these disorders are caused by the production of abnormal proteins or the failure of normal proteins to function properly. By targeting GST, researchers may be able to develop new treatments for these disorders.

Overall, GST is a complex enzyme that plays a crucial role in the immune system and the production of important proteins in the body. Its potential as a drug target or biomarker makes it an important area of research for researchers studying a variety of diseases.

Protein Name: Glutathione S-Transferase (GST) (nonspecified Subtype)

The "Glutathione S-Transferase (GST) Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Glutathione S-Transferase (GST) comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets